RecruitingNCT05133804
Reboxetine and methylphenidate for attention and emotional symptoms in PTSD
About this title
Read the official source — NCT05133804Medication studyAges 20–60Israel
Understand this study
Who could participate?
Listed age limits: 20 years to 60 years.
- Listed locations
- Afula and 2 more locationsSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: June 1, 2022
- Recruitment status
- Recruiting
- Enrollment listed in the registry
- 53
- Sponsor
- University of Haifa
- Sponsor type
- University
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- Israel
- Age range
- From 20 Years to 60 Years
- Official registry ID
- NCT05133804
- Official title
Show the full official title
The Relation Between Attentional, Sensory and Emotional Dysregulation in Adults With Posttraumatic Stress Disorder: a Double-blind, Placebo-controlled Randomized Controlled Trial of the Combined Treatment With Reboxetine and Methylphenidate
Recruitment & locations
Currently recruitingA study may be recruiting, but some locations may no longer be accepting participants. Confirm availability with the research team.
Afula · Haifa · Netanya
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is University of Haifa, a university.
Does this study involve medication?
Yes. The study involves medication, including Methylphenidate, Reboxetine and Placebo.
Who can participate?
Listed age limits: 20 years to 60 years.
Is this study still recruiting?
The registry lists this study as recruiting.
